Design and Objectives of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) Study
- 1 April 1999
- journal article
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 12 (2), 109-116
- https://doi.org/10.1111/j.1540-8183.1999.tb00219.x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic ComplicationJAMA, 1997
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIThe Lancet, 1997
- Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular MedicineNew England Journal of Medicine, 1995
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary InterventionCirculation, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactionsBiochemical Pharmacology, 1987
- Platelet-inhibitor drugs' role in coronary artery diseaseProgress in Cardiovascular Diseases, 1987